Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.
Sham Mailankody, MBBS
Advertisement
Articles by Sham Mailankody, MBBS
Sham Mailankody, MBBS, discusses minimal residual disease negativity in multiple myeloma.
Sham Mailankody, MBBS, discusses results of the CASSIOPEIA trial in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Advertisement
Latest Updated Articles
Dr. Mailankody on CASSIOPEIA Results in Newly Diagnosed Multiple MyelomaPublished: November 6th 2019 | Updated:
Dr. Mailankody on MRD-Negative Status in Multiple MyelomaPublished: November 23rd 2019 | Updated:
Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple MyelomaPublished: December 5th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5